CHRS - Coherus BioSciencesAbout Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $16.23 | Open | |
| Volume | 156 | Market Cap | 1.352B |
| Yield | Last Dividend |
| Coherus BioSciences Earnings Report: Her... | 02/23/21 |
| Coherus BioSciences announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by??? | |
| FDA Accepts Coherus Biosciences' Adalimu... | 02/17/21 |
| The FDA has accepted for review Coherus BioSciences Inc's (NASDAQ: CHRS) marketing application for CHS-1420 and AbbVie's ??? | |
| Coherus surges into immuno-oncology with... | 02/02/21 |
| Shanghai Junshi Biosciences Co. Ltd. could receive an aggregate $1.1 billion from Coherus Biosciences Inc. for the rights to develop and commercialize... | |
| The packed PD-(L)1 game just got another... | 02/01/21 |
| After the majors lined up their PD-(L)1s, a low-profile biosimilars company has stepped up with the latest partnership as the next wave of checkpoints... | |
| Insider Selling: Coherus BioSciences, In... | 01/29/21 |
| Coherus BioSciences, Inc. (NASDAQ:CHRS) CFO Jean-Frederic Viret sold 46,144 shares of the stock in a transaction dated Monday, January 25th. The stock... | |
| STAT+: This tiny, one-drug biotech compa... | 12/16/20 |
| The biosimilar maker Coherus Biosciences is emerging as one of the loudest critics of President Trump???s plan to tie what the U.S. pays for pricey in... | |
| Coherus BioSciences Reports Third Quarte... | 11/05/20 |
| ??? Third Quarter UDENYCA?? Net Sales of $113.6 Million ?????? Net Income of $27.9 Million ?????? Non-GAAP Net Income of $39.7 Million ??? REDWOOD CIT... | |
| Coherus Biosciences (NASDAQ:CHRS) Cut to... | 10/25/20 |
| BidaskClub downgraded shares of Coherus Biosciences (NASDAQ:CHRS) from a sell rating to a strong sell rating in a research report report published on ... | |
| Coherus Biosciences (NASDAQ:CHRS) Rating... | 10/23/20 |
| Coherus Biosciences (NASDAQ:CHRS) was downgraded by equities researchers at BidaskClub from a ???sell??? rating to a ???strong sell??? rating in a res... | |
| Coherus Biosciences (NASDAQ:CHRS) Downgr... | 10/23/20 |
| BidaskClub lowered shares of Coherus Biosciences (NASDAQ:CHRS) from a sell rating to a strong sell rating in a research report sent to investors on Th... | |
| Coherus Biosciences (NASDAQ:CHRS) Stock ... | 10/21/20 |
| Coherus Biosciences Inc (NASDAQ:CHRS)???s stock price dropped 5.9% on Monday following insider selling activity. The company traded as low as $17.03 a... | |
| Coherus BioSciences Reports Second Quart... | 08/06/20 |
| ??? Second Quarter UDENYCA?? Net Sales of $135.7 Million ?????? Net Income of $59.0 Million ?????? Non-GAAP Net Income of $68.3 Million ??? REDWOOD CI... | |
| Coherus BioSciences (CHRS) Earnings Expe... | 04/30/20 |
| Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get pre... | |
| The Daily Biotech Pulse: Pfizer's Eczema... | 03/19/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18)... | |
| Coherus (CHRS) to Report Q4 Earnings: Wh... | 02/24/20 |
| We expect Coherus BioSciences (CHRS) to provide updates on its pipeline when it releases fourth-quarter 2019 results. | |
| Stock To Watch: Coherus Biosciences (CHR... | 02/10/20 |
| Coherus Biosciences (CHRS), a biosimilar company, which is all set to report its fourth-quarter and full-year 2019 financial results on February 27, h... | |
| Is Coherus BioSciences (CHRS) Stock Outp... | 01/07/20 |
| Is (CHRS) Outperforming Other Medical Stocks This Year? | |
| Has Coherus BioSciences (CHRS) Outpaced ... | 12/19/19 |
| Is (CHRS) Outperforming Other Medical Stocks This Year? | |
| Media Advisory - Innovative Lifesaving P... | 11/27/19 |
| Unique partnership program is a direct response to the ' Truth and Reconciliation' Commission's 'call to action: " to increase the number of Indigenou... | |
| The Daily Biotech Pulse: Obseva Sinks On... | 11/07/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 6) A... | |
| Coherus BioSciences (CHRS) Q3 Earnings a... | 11/06/19 |
| Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 75.00% and 19.35%, respectively, for the quarter ended September 2019. Do the n... | |
| The Daily Biotech Pulse: Enanta Aces Mid... | 09/26/19 |
| The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs S... | |
| Coherus BioSciences (CHRS) Upgraded to B... | 09/10/19 |
| Coherus BioSciences (CHRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (B... | |
| Coherus BioSciences (CHRS) Beats Q2 Earn... | 08/01/19 |
| Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 500.00% and 2.94%, respectively, for the quarter ended June 2019. Do the number... | |
| Amgen bid to stop Neulasta biosimilar fa... | 07/29/19 |
| Amgen Inc on Monday lost a bid to revive a lawsuit it filed seeking to block Coherus BioSciences Inc from selling a biosimilar version of its blockbus... | |
| The Daily Biotech Pulse: Roche's Flu Dru... | 07/03/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 2) A... | |
| The Daily Biotech Pulse: Celyad To Advan... | 07/02/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 1) A... | |
| Coherus BioSciences (CHRS) Upgraded to S... | 06/27/19 |
| Coherus BioSciences (CHRS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This... | |
| The Daily Biotech Pulse: ContraVir's Vol... | 06/21/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 20) ... | |
| 3 Gene Therapy Stocks For A Biotech Port... | 05/20/19 |
| No summary available. | |
| Date | 2021-02-24 (AMC) | Est. (EPS/Rev.) | $0.23/ 115.12M |
| Actual (EPS/Rev.) | $0.23/ $110.42 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
